| Peer-Reviewed

The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar

Received: 8 December 2021     Accepted: 6 January 2022     Published: 12 January 2022
Views:       Downloads:
Abstract

Background: Hepatitis B virus is one of the causes of the major health problem throughout the world. Hepatitis B vaccine is one way to control HBV infections effectively. The prevalence of HB infection shows a decreased effectivity of Hepatitis B vaccination. Objective: To discover the differences in anti-HBs levels between two schedules of vaccination recommended by the Indonesian Pediatric Society (at 2, 4, 6 months vs 2, 3, 4 months of age). Methods: This was an observational study on healthy babies comparing the effect of two treatment groups, each consisting of 30 subjects. Subjects were chosen by stratified random sampling. Blood samples were withdrawn three months after the subjects received their last dose of Hepatitis B vaccination, either in 2, 4, 6 months schedule (Group 1) or in 2, 3, 4 months schedule (Group 2). We used the independent t-test to assess the mean differences between the anti-HBs levels of the two groups. A p-value of<0.05 was considered statistically significant. Results: We found a significant difference in anti-HBs levels between Group 1 and Group 2 (820.06 mIU/ml vs 540.54 mIU/ml, respectively, p=0.002). Conclusion: Both vaccination schedules produced protective anti-HBs levels three months after the completed schedule. The anti-HBs level in group 1 produced higher anti-HBs level compared to Group 2.

Published in American Journal of Pediatrics (Volume 8, Issue 1)
DOI 10.11648/j.ajp.20220801.12
Page(s) 6-9
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Children, Hepatitis B, Anti-HBs, Vaccination, Indonesia

References
[1] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63 (1): 261-283. doi: 10.1002/hep.28156.
[2] World Health Organization. WHO manual for the establishment of national and other secondary standards for vaccines. Geneva: World Health Organization Publication; 2011. Available at: https://apps.who.int/iris/handle/10665/70669.
[3] Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997; 336 (26): 1855-1859. doi: 10.1056/NEJM199706263362602.
[4] Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology. 2004; 39 (1): 58-63. doi: 10.1002/hep.20006.
[5] Armstrong GL, Mast EE, Wojczynski M, Margolis HS. Childhood hepatitis B virus infections in the United States before hepatitis B immunisation. Pediatrics. 2001; 108 (5): 1123-1128. doi: 10.1542/peds.108.5.1123.
[6] Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 2000; 284 (23): 3040-3042. doi: 10.1001/jama.284.23.3040.
[7] Chongsrisawat V, Theamboonlers A, Khwanjaipanich S, Owatanapanich S, Sinlaparatsamee S, Poovorawan Y. Humoral immune response following hepatitis B vaccine booster dose in children with and without prior immunisation. Southeast Asian J Trop Med Public Health. 2000; 31 (4): 623-626.
[8] Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003; 187 (1): 134-138. doi: 10.1086/345871.
[9] Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J. 2004; 23 (7): 650-655. doi: 10.1097/01.inf.0000130952.96259.fd.
[10] Banatvala JE, Van Damme P. Hepatitis B vaccine – do we need boosters? Journal of Viral Hepatitis. 2003; 10: 1-6. doi: 10.1046/j.1365-2893.2003.00400.x.
[11] Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006; 18 (4): 4-9.
[12] Van Damme P, Moiseeva A, Marichev I, Kervyn AD, Booy R, Kuriyakose S, et al. Five years follow-up following two or three doses of a hepatitis B vaccine in adolescents aged 11-15 years: a randomised controlled study. BMC Infect Dis. 2010; 10: 357. doi: 10.1186/1471-2334-10-357.
[13] Girisha KM, Kamat JR, Nataraj G. Immunological response to two hepatitis B vaccines administered in two different schedules. Indian J Pediatr. 2006; 73 (6): 489-491. doi: 10.1007/BF02759892.
[14] IPS Immunisation Task Force. Jadwal imunisasi rekomendasi IDAI (article in Indonesian). Sari Pediatri. 2000; 2 (1): 43-47. doi: 10.14238/sp2.1.2000.43-7.
[15] Gunardi H, Kartasasmita CB, Hadinegoro SRS, Satari HI, Oswari H, Pusponegoro HD, et al. Jadwal Imunisasi Anak Usia 0–18 Tahun Rekomendasi Ikatan Dokter Anak Indonesia 2017 (article in Indonesian). Sari Pediatri. 2017; 18 (5): 417-22. doi: 10.14238/sp18.5.2017.417-22.
[16] Zhang X, Wang J, Chen X, Yu M, Yu S, Sun Y, et al. Short-term immunogenicity of standard and accelerated hepatitis B virus vaccination schedules in healthy adults: a comparative field study in China. Biosci Rep. 2018; 38 (5): BSR20180846. doi: 10.1042/BSR20180846.
[17] Rusmil K. Melengkapi/Mengejar Imunisasi (article in Indonesian). Indonesian Pediatric Society. Last updated: May 30, 2015. Last accessed: May 23, 2020. Available at: https://www.idai.or.id/artikel/klinik/imunisasi/melengkapi-mengejar-imunisasi-bagian-i.
Cite This Article
  • APA Style

    Vania Catleya Estina, I Gusti Ngurah Sanjaya Putra, Dyah Kanya Wati, Hendra Santoso, I Gusti Agung Ngurah Sugitha Adnyana, et al. (2022). The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar. American Journal of Pediatrics, 8(1), 6-9. https://doi.org/10.11648/j.ajp.20220801.12

    Copy | Download

    ACS Style

    Vania Catleya Estina; I Gusti Ngurah Sanjaya Putra; Dyah Kanya Wati; Hendra Santoso; I Gusti Agung Ngurah Sugitha Adnyana, et al. The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar. Am. J. Pediatr. 2022, 8(1), 6-9. doi: 10.11648/j.ajp.20220801.12

    Copy | Download

    AMA Style

    Vania Catleya Estina, I Gusti Ngurah Sanjaya Putra, Dyah Kanya Wati, Hendra Santoso, I Gusti Agung Ngurah Sugitha Adnyana, et al. The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar. Am J Pediatr. 2022;8(1):6-9. doi: 10.11648/j.ajp.20220801.12

    Copy | Download

  • @article{10.11648/j.ajp.20220801.12,
      author = {Vania Catleya Estina and I Gusti Ngurah Sanjaya Putra and Dyah Kanya Wati and Hendra Santoso and I Gusti Agung Ngurah Sugitha Adnyana and Komang Ayu Witarini},
      title = {The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar},
      journal = {American Journal of Pediatrics},
      volume = {8},
      number = {1},
      pages = {6-9},
      doi = {10.11648/j.ajp.20220801.12},
      url = {https://doi.org/10.11648/j.ajp.20220801.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajp.20220801.12},
      abstract = {Background: Hepatitis B virus is one of the causes of the major health problem throughout the world. Hepatitis B vaccine is one way to control HBV infections effectively. The prevalence of HB infection shows a decreased effectivity of Hepatitis B vaccination. Objective: To discover the differences in anti-HBs levels between two schedules of vaccination recommended by the Indonesian Pediatric Society (at 2, 4, 6 months vs 2, 3, 4 months of age). Methods: This was an observational study on healthy babies comparing the effect of two treatment groups, each consisting of 30 subjects. Subjects were chosen by stratified random sampling. Blood samples were withdrawn three months after the subjects received their last dose of Hepatitis B vaccination, either in 2, 4, 6 months schedule (Group 1) or in 2, 3, 4 months schedule (Group 2). We used the independent t-test to assess the mean differences between the anti-HBs levels of the two groups. A p-value ofResults: We found a significant difference in anti-HBs levels between Group 1 and Group 2 (820.06 mIU/ml vs 540.54 mIU/ml, respectively, p=0.002). Conclusion: Both vaccination schedules produced protective anti-HBs levels three months after the completed schedule. The anti-HBs level in group 1 produced higher anti-HBs level compared to Group 2.},
     year = {2022}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Difference of Anti-HBs Levels in Babies Vaccinated with Hepatitis B Vaccine Between at 2, 4, 6 Months with 2, 3, 4 Months Schedule in Denpasar
    AU  - Vania Catleya Estina
    AU  - I Gusti Ngurah Sanjaya Putra
    AU  - Dyah Kanya Wati
    AU  - Hendra Santoso
    AU  - I Gusti Agung Ngurah Sugitha Adnyana
    AU  - Komang Ayu Witarini
    Y1  - 2022/01/12
    PY  - 2022
    N1  - https://doi.org/10.11648/j.ajp.20220801.12
    DO  - 10.11648/j.ajp.20220801.12
    T2  - American Journal of Pediatrics
    JF  - American Journal of Pediatrics
    JO  - American Journal of Pediatrics
    SP  - 6
    EP  - 9
    PB  - Science Publishing Group
    SN  - 2472-0909
    UR  - https://doi.org/10.11648/j.ajp.20220801.12
    AB  - Background: Hepatitis B virus is one of the causes of the major health problem throughout the world. Hepatitis B vaccine is one way to control HBV infections effectively. The prevalence of HB infection shows a decreased effectivity of Hepatitis B vaccination. Objective: To discover the differences in anti-HBs levels between two schedules of vaccination recommended by the Indonesian Pediatric Society (at 2, 4, 6 months vs 2, 3, 4 months of age). Methods: This was an observational study on healthy babies comparing the effect of two treatment groups, each consisting of 30 subjects. Subjects were chosen by stratified random sampling. Blood samples were withdrawn three months after the subjects received their last dose of Hepatitis B vaccination, either in 2, 4, 6 months schedule (Group 1) or in 2, 3, 4 months schedule (Group 2). We used the independent t-test to assess the mean differences between the anti-HBs levels of the two groups. A p-value ofResults: We found a significant difference in anti-HBs levels between Group 1 and Group 2 (820.06 mIU/ml vs 540.54 mIU/ml, respectively, p=0.002). Conclusion: Both vaccination schedules produced protective anti-HBs levels three months after the completed schedule. The anti-HBs level in group 1 produced higher anti-HBs level compared to Group 2.
    VL  - 8
    IS  - 1
    ER  - 

    Copy | Download

Author Information
  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Department of Child Health, Medical Faculty of Udayana University, Sanglah General Hospital, Denpasar, Bali, Indonesia

  • Sections